

Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



02 November, 2019

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 2nd November 2019.

We refer to the above mentioned subject, we herewith intimate the Exchange that the Board of Directors at their meeting held on 2nd November 2019 has considered and approved interalia the following:

- a) Unaudited Financial results and Limited Review Report for the quarter and half year ended 30th September, 2019 which are enclosed herewith.
- b) The Board has considered and approved the resignation of the Chief Financial Officer of the Company Mr. Phani Srinath.

Kindly note that the meeting commenced at 12:30 AM and concluded at 05:30 PM

This is for the information and records of the Exchange, Please.

Thanking You,
Yours Faithfully,

For **Krebs Biochemicals & Industries Limited**


Taruni Banda
Company Secretary



Encl as above

CIN: I 24110AP1991PIC103912

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2019

(Rs. In lacs)

1	The above results have been reviewed by the Audit Committee at its meeting held on 02nd November 2019 and approved by the Board of Directors of the Company at its meeting held on 02nd November 2019. The results are subjected to limited review by statutory auditors.
2	The Company is operating in one segment only hence no segment results have been disclosed.
3	The Company has adopted Ind AS-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the Company.
4	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.

Date: 02.11.2019

Avinash Ravi
Managing Director
DIN : 01616152

DIN : 01616152

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalle

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034


Statement of Assets and Liabilities

Rs. In Lacs

Particulars	As at	As at
	30.09.2019	31.03.2019
	Un Audited	Audited
ASSETS		
Non Current Assets		
(a) Property, Plant and Equipment	9,691.69	9,908.46
(b) Capital Work in Progress	809.24	163.45
(c) Other Intangible Assets	205.28	218.29
(d) Intangible assets under development	184.71	184.71
(e) Financial Assets	153.11	145.34
(f) Other Non Current Assets	352.91	518.58
Total Non Current Assets	11,396.93	11,138.83
Current Assets		
(a) Inventories	1,080.78	896.37
(b) Financial Assets		
(i) Trade Receivables	134.40	291.09
(ii) Cash & Cash Equivalents	131.12	1,731.89
(iii) Other Financial Assets	60.82	49.42
(c) Other Current Assets	200.35	128.90
Total Current Assets	1,607.47	3,097.67
Total Assets	13,004.40	14,236.50
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	1,663.06	1,663.06
(b) Other Equity	(4,704.38)	(3,091.97)
Total Equity	(3,041.33)	(1,428.91)
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities		
(i) Long Term Borrowings	5,122.71	5,022.71
(ii) Other Financial Liabilities	413.66	350.47
(b) Provisions	227.40	227.40
(c) Retirement benefit obligations	176.89	176.89
(d) Other Non Current Liabilities	4,462.52	4,401.79
Total Non Current Liabilities	10,403.18	10,179.26
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings		
(ii) Trade Payables		
(a) Total outstanding dues of micro and small enterprises	376.86	321.79
(b) Total outstanding dues of creditors other than micro and small enterprises	2,087.62	1,824.49
(iii) Other Financial Liabilities		-
(b) Other Current Liabilities	3,011.47	3,197.23
(c) Provisions	89.55	65.59
(d) Retirement benefit obligations	77.04	77.04
Total Current Liabilities	5,642.54	5,486.15
Total Equity and Liabilities	13,004.40	14,236.50

Place: Hyderabad

Date: 02.11.2019


AVINASH RAVI
Managing Director

DIN: 01616152

KREBS BIOCHEMICALS & INDUSTRIES LIMITED

CIN:L24110AP1991PLC103912


Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

Cash Flow Statement for the Half Year Ended September 30, 2019

(Rs in Lacs)

Particulars	Half Year Ended 30.09.2019	Half Year Ended 30.09.2018
Cash Flow from Operating Activities		
Net Profit before tax and exceptional items	(1,543.37)	(833.87)
Adjustments for:		
Depreciation and Amortisation Expenses	229.78	214.74
Financial Charges	323.56	288.13
Other Income	(24.32)	(4.47)
Other Comprehensive Income	(69.03)	(52.01)
Operating Profit before Working Capital Changes	(1,083.39)	(387.48)
Changes in Working Capital		
(Increase)/Decrease in Inventories	(184.41)	368.90
(Increase)/Decrease in Trade Receivables	156.69	(147.01)
(Increase)/Decrease in Other Financial Assets	(11.40)	9.64
(Increase)/Decrease in Other Current Assets	(71.45)	7.17
(Increase)/Decrease in Financial Assets	(7.77)	(27.44)
(Increase)/Decrease in Other Non Current Assets	165.67	(97.74)
Increase/(Decrease) in Non Current Provisions	-	5.90
Increase/(Decrease) in Retirement Benefit obligations	-	4.60
Increase/(Decrease) in Current Provisions	23.96	15.09
Increase/(Decrease) in Retirement Benefit obligations	-	(0.56)
Increase/(Decrease) in Trade Payables	318.17	125.30
Increase/(Decrease) in Other Current Liabilities	(185.76)	470.01
Cash generated from Operations	203.72	733.85
Financial Charges	(323.56)	(288.13)
Net Cash Flow from Operating Activities	(1,203.23)	58.24
(Increase)/Decrease of Capital Work-in-Progress	(645.79)	(93.29)
(Increase)/Decrease of Other Intangible Assets	-	(15.66)
Other Income	24.32	4.47
Cash Flow from Investing Activities	(621.47)	(104.48)
Increase/(Decrease) in long term borrowings	100.00	(71.16)
Increase/(Decrease) in Other Financial Liabilities	63.19	54.61
Increase/(Decrease) in Other Non Current Liabilities	60.73	25.97
Cash Flow from Financing Activities	223.92	9.41
Net Increase (Decrease) in Cash and Cash equivalents	(1,600.77)	(36.83)
Cash and Cash equivalents as at the beginning of the year	1,731.89	41.84
Cash and Cash equivalents at the end of the year	131.12	5.01

• AVINASH RAVI
Managing Director
DIN: 01616152

Place: Hyderabad

Date: 02.11.2019




Limited Review Report

**Review Report to
The Board of Directors,
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

- a) We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the company") for the quarter ended **30th September, 2019** and the year to date from 1st April 2019 to 30th September 2019 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with SEBI circular No CIR/CFD/FAC/62/2016 dated 5th July 2016.
- b) The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
- c) We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- d) Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim financial reporting (Ind AS 34) specified under section 133 of the Companies Act 2013 read with relevant rules issued thereafter and other recognized accounting practices and policies has disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, read with circular No. CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bhavani & Co.
Chartered Accountants
Firm Registration No: 012139S

CA S Kavitha Padma
Partner
Membership no: 229966



Place : Hyderabad
Date : 02/11/2019